Last reviewed · How we verify
NCT07506239
Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma
NA trial testing Laser Interstitial Thermal Therapy (LITT) in Low-grade Glioma in 40 participants. Currently enrolling.
1 January 2030
Quick facts
| Lead sponsor | University of California, San Francisco |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 25 March 2026 |
| Primary completion | 1 January 2030 |
| Estimated completion | 1 January 2031 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Laser Interstitial Thermal Therapy (LITT)
- Magnetic resonance imaging (MRI)
- Questionnaires
Conditions studied
- Low-grade Glioma — all drugs for Low-grade Glioma →
- Recurrent Low Grade Glioma — all drugs for Recurrent Low Grade Glioma →
- Low Grade Glioma of Brain — all drugs for Low Grade Glioma of Brain →
- Pediatric Cancer — all drugs for Pediatric Cancer →
Sponsor
University of California, San Francisco
Who can join
Adults 2 to 25, any sex, with Low-grade Glioma or Recurrent Low Grade Glioma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the efficacy of Laser Interstitial Thermal Therapy (LITT) in treating recurrent or progressive, low-grade gliomas (LGG) in pediatric, adolescent and young adult patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07506239
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Laser Interstitial Thermal Therapy (LITT)
Trials testing the same drug.
- NCT05318612 — Effectiveness of MR-guided LITT Therapy in Irresectable Glioblastoma (EMITT) · Phase 3 · active not recruiting
Other recruiting trials for Low-grade Glioma
Currently open trials in the same condition.
- NCT07110246 — Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas · Phase 2 · recruiting
- NCT06684795 — FG001 in Subjects with Meningiomas or Presumed Low-Grade Gliomas Scheduled for Neurosurgery · Phase 2 · recruiting
- NCT06610851 — Monitoring of Patients With Low-grade Gliomas Using Circulating miRNA · recruiting
- NCT06381570 — Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Glioma · EARLY_PHASE1 · recruiting
- NCT06104488 — A Study of Avutometinib for People With Solid Tumor Cancers · Phase 1 · recruiting
Other University of California, San Francisco trials
Trials by the same sponsor.
- NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
- NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
- NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
- NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
- NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07506239 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
- Last refreshed: 1 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07506239.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing